Keyword: Otezla

Advertising agency word cloud image

The top 10 ad spenders in Big Pharma for 2019

Direct-to-consumer drug ads tend to strike a dissonant chord. However, fan and foe can count on one thing: Prescription DTC advertising is here to stay. The evidence? Surviving more than 20 years of numerous legal, regulatory and perception challenges on its way to becoming a $6 billion-plus annual industry.
Bristol-Myers Squibb

1. Bristol-Myers Squibb/Celgene

The year 2019 kicked off with the biopharma industry’s largest acquisition proposal ever: Bristol-Myers Squibb unveiled it would buy Celgene in a cash and stock deal valued at $74 billion.
People shaking hands across a desk that has computer and papers on it

The top 10 largest biopharma M&A deals in 2019

Biopharma M&A got a big boost moneywise in 2019. The three largest delivered more than $150 billion, with Bristol-Myers Squibb's $74 billion takeover of Celgene setting a new record. Oncology was still a hot theme, stringing through a whole year of big dealmaking headlines, just as gene therapy gained popularity.